Cargando…
A Placebo-Controlled Trial of Cannabinoid Treatment for Disruptive Behavior in Children and Adolescents with Autism Spectrum Disorder: Effects on Sleep Parameters as Measured by the CSHQ
Autism spectrum disorder (ASD) is often associated with debilitating sleep disturbances. While anecdotal evidence suggests the positive effect of cannabinoids, randomized studies are lacking. Here, we report the effects of cannabinoid treatment on the sleep of 150 children and adolescents with ASD,...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9312464/ https://www.ncbi.nlm.nih.gov/pubmed/35884990 http://dx.doi.org/10.3390/biomedicines10071685 |
_version_ | 1784753846989357056 |
---|---|
author | Schnapp, Aviad Harel, Moria Cayam-Rand, Dalit Cassuto, Hanoch Polyansky, Lola Aran, Adi |
author_facet | Schnapp, Aviad Harel, Moria Cayam-Rand, Dalit Cassuto, Hanoch Polyansky, Lola Aran, Adi |
author_sort | Schnapp, Aviad |
collection | PubMed |
description | Autism spectrum disorder (ASD) is often associated with debilitating sleep disturbances. While anecdotal evidence suggests the positive effect of cannabinoids, randomized studies are lacking. Here, we report the effects of cannabinoid treatment on the sleep of 150 children and adolescents with ASD, as part of a double-blind, placebo-controlled study that assessed the impact of cannabinoid treatment on behavior (NCT02956226). Participants were randomly assigned to one of the following three treatments: (1) whole-plant cannabis extract, containing cannabidiol (CBD) and Δ9-Tetrahydrocannabinol (THC) in a 20:1 ratio, (2) purified CBD and THC extract in the same ratio, and (3) an oral placebo. After 12 weeks of treatment (Period 1) and a 4-week washout period, participants crossed over to a predetermined, second 12-week treatment (Period 2). Sleep disturbances were assessed using the Children’s Sleep-Habit Questionnaire (CSHQ). We found that the CBD-rich cannabinoid treatment was not superior to the placebo treatment in all aspects of sleep measured by the CSHQ, including bedtime resistance, sleep-onset delay, and sleep duration. Notably, regardless of the treatment (cannabinoids or placebo), improvements in the CSHQ total score were associated with improvements in the autistic core symptoms, as indicated by the Social Responsiveness Scale total scores (Period 1: r = 0.266, p = 0.008; Period 2: r = 0.309, p = 0.004). While this study failed to demonstrate that sleep improvements were higher with cannabinoids than they were with the placebo treatment, further studies are required. |
format | Online Article Text |
id | pubmed-9312464 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93124642022-07-26 A Placebo-Controlled Trial of Cannabinoid Treatment for Disruptive Behavior in Children and Adolescents with Autism Spectrum Disorder: Effects on Sleep Parameters as Measured by the CSHQ Schnapp, Aviad Harel, Moria Cayam-Rand, Dalit Cassuto, Hanoch Polyansky, Lola Aran, Adi Biomedicines Article Autism spectrum disorder (ASD) is often associated with debilitating sleep disturbances. While anecdotal evidence suggests the positive effect of cannabinoids, randomized studies are lacking. Here, we report the effects of cannabinoid treatment on the sleep of 150 children and adolescents with ASD, as part of a double-blind, placebo-controlled study that assessed the impact of cannabinoid treatment on behavior (NCT02956226). Participants were randomly assigned to one of the following three treatments: (1) whole-plant cannabis extract, containing cannabidiol (CBD) and Δ9-Tetrahydrocannabinol (THC) in a 20:1 ratio, (2) purified CBD and THC extract in the same ratio, and (3) an oral placebo. After 12 weeks of treatment (Period 1) and a 4-week washout period, participants crossed over to a predetermined, second 12-week treatment (Period 2). Sleep disturbances were assessed using the Children’s Sleep-Habit Questionnaire (CSHQ). We found that the CBD-rich cannabinoid treatment was not superior to the placebo treatment in all aspects of sleep measured by the CSHQ, including bedtime resistance, sleep-onset delay, and sleep duration. Notably, regardless of the treatment (cannabinoids or placebo), improvements in the CSHQ total score were associated with improvements in the autistic core symptoms, as indicated by the Social Responsiveness Scale total scores (Period 1: r = 0.266, p = 0.008; Period 2: r = 0.309, p = 0.004). While this study failed to demonstrate that sleep improvements were higher with cannabinoids than they were with the placebo treatment, further studies are required. MDPI 2022-07-13 /pmc/articles/PMC9312464/ /pubmed/35884990 http://dx.doi.org/10.3390/biomedicines10071685 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Schnapp, Aviad Harel, Moria Cayam-Rand, Dalit Cassuto, Hanoch Polyansky, Lola Aran, Adi A Placebo-Controlled Trial of Cannabinoid Treatment for Disruptive Behavior in Children and Adolescents with Autism Spectrum Disorder: Effects on Sleep Parameters as Measured by the CSHQ |
title | A Placebo-Controlled Trial of Cannabinoid Treatment for Disruptive Behavior in Children and Adolescents with Autism Spectrum Disorder: Effects on Sleep Parameters as Measured by the CSHQ |
title_full | A Placebo-Controlled Trial of Cannabinoid Treatment for Disruptive Behavior in Children and Adolescents with Autism Spectrum Disorder: Effects on Sleep Parameters as Measured by the CSHQ |
title_fullStr | A Placebo-Controlled Trial of Cannabinoid Treatment for Disruptive Behavior in Children and Adolescents with Autism Spectrum Disorder: Effects on Sleep Parameters as Measured by the CSHQ |
title_full_unstemmed | A Placebo-Controlled Trial of Cannabinoid Treatment for Disruptive Behavior in Children and Adolescents with Autism Spectrum Disorder: Effects on Sleep Parameters as Measured by the CSHQ |
title_short | A Placebo-Controlled Trial of Cannabinoid Treatment for Disruptive Behavior in Children and Adolescents with Autism Spectrum Disorder: Effects on Sleep Parameters as Measured by the CSHQ |
title_sort | placebo-controlled trial of cannabinoid treatment for disruptive behavior in children and adolescents with autism spectrum disorder: effects on sleep parameters as measured by the cshq |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9312464/ https://www.ncbi.nlm.nih.gov/pubmed/35884990 http://dx.doi.org/10.3390/biomedicines10071685 |
work_keys_str_mv | AT schnappaviad aplacebocontrolledtrialofcannabinoidtreatmentfordisruptivebehaviorinchildrenandadolescentswithautismspectrumdisordereffectsonsleepparametersasmeasuredbythecshq AT harelmoria aplacebocontrolledtrialofcannabinoidtreatmentfordisruptivebehaviorinchildrenandadolescentswithautismspectrumdisordereffectsonsleepparametersasmeasuredbythecshq AT cayamranddalit aplacebocontrolledtrialofcannabinoidtreatmentfordisruptivebehaviorinchildrenandadolescentswithautismspectrumdisordereffectsonsleepparametersasmeasuredbythecshq AT cassutohanoch aplacebocontrolledtrialofcannabinoidtreatmentfordisruptivebehaviorinchildrenandadolescentswithautismspectrumdisordereffectsonsleepparametersasmeasuredbythecshq AT polyanskylola aplacebocontrolledtrialofcannabinoidtreatmentfordisruptivebehaviorinchildrenandadolescentswithautismspectrumdisordereffectsonsleepparametersasmeasuredbythecshq AT aranadi aplacebocontrolledtrialofcannabinoidtreatmentfordisruptivebehaviorinchildrenandadolescentswithautismspectrumdisordereffectsonsleepparametersasmeasuredbythecshq AT schnappaviad placebocontrolledtrialofcannabinoidtreatmentfordisruptivebehaviorinchildrenandadolescentswithautismspectrumdisordereffectsonsleepparametersasmeasuredbythecshq AT harelmoria placebocontrolledtrialofcannabinoidtreatmentfordisruptivebehaviorinchildrenandadolescentswithautismspectrumdisordereffectsonsleepparametersasmeasuredbythecshq AT cayamranddalit placebocontrolledtrialofcannabinoidtreatmentfordisruptivebehaviorinchildrenandadolescentswithautismspectrumdisordereffectsonsleepparametersasmeasuredbythecshq AT cassutohanoch placebocontrolledtrialofcannabinoidtreatmentfordisruptivebehaviorinchildrenandadolescentswithautismspectrumdisordereffectsonsleepparametersasmeasuredbythecshq AT polyanskylola placebocontrolledtrialofcannabinoidtreatmentfordisruptivebehaviorinchildrenandadolescentswithautismspectrumdisordereffectsonsleepparametersasmeasuredbythecshq AT aranadi placebocontrolledtrialofcannabinoidtreatmentfordisruptivebehaviorinchildrenandadolescentswithautismspectrumdisordereffectsonsleepparametersasmeasuredbythecshq |